Back on Capitol Hill, pharmaceutical companies are preparing to challenge a new resolution that would prevent them from buying out generic rivals to keep cheaper drugs off the market. Democratic Senator Patrick Leahy introduced the measure on Wednesday. Appearing before the Senate Judiciary Committee, a Federal Trade Commission official testified U.S. drug law gives generic companies more incentive to be bought off than to develop cheaper alternatives to branded and more expensive medications.